A dose-comparative endocrine-clinical study of leuprorelin in premenopausal breast cancer patients.

Twelve premenopausal patients with advanced breast cancer were randomised to receive 3.75 or 7.5 mg of a slow release formulation of the luteinising hormone releasing hormone agonist leuprorelin once every 4 weeks. All patients were oestrogen receptor positive or unknown. Serum levels of gonadotroph...

Descripción completa

Detalles Bibliográficos
Autores principales: Dowsett, M., Mehta, A., Mansi, J., Smith, I. E.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1990
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1971512/
https://www.ncbi.nlm.nih.gov/pubmed/2123115

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1971512/
https://www.ncbi.nlm.nih.gov/pubmed/2123115

Ejemplares similares